Evidence map›Paper›PMID 27048872›Full record

ArticleNature communications2016

GATA3 induces human T-cell commitment by restraining Notch activity and repressing NK-cell fate.

Inge Van de Walle, Anne-Catherine Dolens, Kaat Durinck, Katrien De Mulder, Wouter Van Loocke, Sagar Damle, Els Waegemans, Jelle De Medts, Imke Velghe, Magda De Smedt and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 66 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. T Cell Development: From T-Lineage Specification to Intrathymic Maturation.Advances in experimental medicine and biology · 2025
    Review
  7. Transcriptional network dynamics in early T cell development.The Journal of experimental medicine · 2024
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. γδ T cells: origin and fate, subsets, diseases and immunotherapy.Signal transduction and targeted therapy · 2023
    Review
  14. Circulating IRF8-expressing CD123Trends in immunology · 2023
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 2 countries.

Inge Van de WalleFaculty of Medicine and Health Sciences, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, University Hospital Ghent, 4BlokA, De Pintelaan 185, B-9000 Ghent, Belgium.
Anne-Catherine DolensFaculty of Medicine and Health Sciences, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, University Hospital Ghent, 4BlokA, De Pintelaan 185, B-9000 Ghent, Belgium.
Kaat DurinckCenter for Medical Genetics, Ghent University, University Hospital Ghent, Medical Research Building 1, De Pintelaan 185, B-9000 Ghent, Belgium.
Katrien De MulderFaculty of Medicine and Health Sciences, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, University Hospital Ghent, 4BlokA, De Pintelaan 185, B-9000 Ghent, Belgium.
Wouter Van LoockeCenter for Medical Genetics, Ghent University, University Hospital Ghent, Medical Research Building 1, De Pintelaan 185, B-9000 Ghent, Belgium.
Sagar DamleDivision of Biology &Biological Engineering, California Institute of Technology, MC156-29, 1200 East California Boulevard, Pasadena, California 91125, USA.
Els WaegemansFaculty of Medicine and Health Sciences, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, University Hospital Ghent, 4BlokA, De Pintelaan 185, B-9000 Ghent, Belgium.
Jelle De MedtsFaculty of Medicine and Health Sciences, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, University Hospital Ghent, 4BlokA, De Pintelaan 185, B-9000 Ghent, Belgium.
Imke VelgheFaculty of Medicine and Health Sciences, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, University Hospital Ghent, 4BlokA, De Pintelaan 185, B-9000 Ghent, Belgium.
Magda De SmedtFaculty of Medicine and Health Sciences, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, University Hospital Ghent, 4BlokA, De Pintelaan 185, B-9000 Ghent, Belgium.
Bart VandekerckhoveFaculty of Medicine and Health Sciences, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, University Hospital Ghent, 4BlokA, De Pintelaan 185, B-9000 Ghent, Belgium.
Tessa KerreFaculty of Medicine and Health Sciences, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, University Hospital Ghent, 4BlokA, De Pintelaan 185, B-9000 Ghent, Belgium.
Jean PlumFaculty of Medicine and Health Sciences, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, University Hospital Ghent, 4BlokA, De Pintelaan 185, B-9000 Ghent, Belgium.
Georges LeclercqFaculty of Medicine and Health Sciences, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, University Hospital Ghent, 4BlokA, De Pintelaan 185, B-9000 Ghent, Belgium.
Ellen V RothenbergDivision of Biology &Biological Engineering, California Institute of Technology, MC156-29, 1200 East California Boulevard, Pasadena, California 91125, USA.
Pieter Van VlierbergheCenter for Medical Genetics, Ghent University, University Hospital Ghent, Medical Research Building 1, De Pintelaan 185, B-9000 Ghent, Belgium.
Frank SpelemanCenter for Medical Genetics, Ghent University, University Hospital Ghent, Medical Research Building 1, De Pintelaan 185, B-9000 Ghent, Belgium.
Tom TaghonFaculty of Medicine and Health Sciences, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, University Hospital Ghent, 4BlokA, De Pintelaan 185, B-9000 Ghent, Belgium.
Ghent University Hospital · BECalifornia Institute of Technology · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The gradual reprogramming of haematopoietic precursors into the T-cell fate is characterized by at least two sequential developmental stages. Following Notch1-dependent T-cell lineage specification during which the first T-cell lineage genes are expressed and myeloid and dendritic cell potential is lost, T-cell specific transcription factors subsequently induce T-cell commitment by repressing residual natural killer (NK)-cell potential. How these processes are regulated in human is poorly understood, especially since efficient T-cell lineage commitment requires a reduction in Notch signalling activity following T-cell specification. Here, we show that GATA3, in contrast to TCF1, controls human T-cell lineage commitment through direct regulation of three distinct processes: repression of NK-cell fate, upregulation of T-cell lineage genes to promote further differentiation and restraint of Notch activity. Repression of the Notch1 target gene DTX1 hereby is essential to prevent NK-cell differentiation. Thus, GATA3-mediated positive and negative feedback mechanisms control human T-cell lineage commitment.

Indexed as

Feedback, PhysiologicalCell DifferentiationCell LineageCellular ReprogrammingChildGATA3 Transcription FactorGene Expression Regulation, DevelopmentalHematopoietic Stem CellsHepatocyte Nuclear Factor 1-alphaHumansKiller Cells, NaturalPrimary Cell CultureReceptor, Notch1Signal TransductionThymocytesUbiquitin-Protein LigasesDTX1 protein, humanGATA3 protein, humanGATA3 Transcription FactorHepatocyte Nuclear Factor 1-alphaHNF1A protein, humanNOTCH1 protein, humanReceptor, Notch1Ubiquitin-Protein Ligases

Identifiers

PMID27048872
PMCPMC4823830
OpenAlexW2312705855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.